Varicocele is one of the most common findings in male reproductive medicine and one of the most narrowly discussed. It appears in roughly 15 percent of adult men and in a substantially higher proportion of men evaluated for infertility, and the clinical conversation almost always stops at sperm parameters. The relationship between varicocele and erectile dysfunction has received far less attention, despite a coherent mechanistic rationale and a body of evidence that has accumulated steadily since the early 2010s. The link runs primarily through testosterone rather than through penile blood flow, which makes it a useful case study in how erectile dysfunction can originate somewhere other than the penis.
What a Varicocele Is, and Why It Is More Than a Fertility Problem
A varicocele is an abnormal dilation of the pampiniform plexus, the network of veins draining the testis. It arises from incompetent or absent valves in the internal spermatic vein, allowing retrograde blood flow and venous pooling within the scrotum. The left side is affected in the large majority of cases, an anatomical consequence of the left internal spermatic vein draining at a right angle into the left renal vein rather than directly into the inferior vena cava.
The pathophysiological consequences are well characterised. Venous stasis raises intrascrotal temperature by one to two degrees Celsius, which is sufficient to impair the temperature-sensitive processes of the testis. Stasis also produces local hypoxia, reflux of renal and adrenal metabolites, and a marked increase in oxidative stress within the testicular microenvironment.
The conventional focus is on what this does to spermatogenesis, and a 2026 comprehensive review in the Journal of Clinical Medicine reaffirms varicocele's position among the most common and correctable urological causes of male infertility [1]. But the germinal epithelium is not the only tissue exposed to that environment. The Leydig cells, which produce testosterone, sit in the interstitium of the same organ and are subject to the same heat, hypoxia, and oxidative burden.
The Testosterone Link: Leydig Cell Dysfunction
This is where the connection to erectile function is established. Testosterone is not a peripheral consideration in erectile physiology. It maintains libido and central sexual drive, supports the expression and activity of nitric oxide synthase within cavernosal tissue, and preserves the structural integrity of cavernosal smooth muscle — androgen deficiency promotes fibrosis and fatty replacement of that smooth muscle over time.
A review in Urologic Clinics of North America examining testosterone and varicocele concluded that the presence of a varicocele is associated with lower serum testosterone, and that varicocelectomy may reverse some of the adverse effects on androgen production [2]. The proposed mechanism is direct: chronic heat and oxidative stress impair Leydig cell steroidogenesis, reducing testosterone output from the affected testis.
The consequence for erectile function follows from that. Reduced testosterone lowers central sexual drive and degrades the peripheral machinery that generates an erection. It also blunts the response to PDE5 inhibitor therapy, since those drugs amplify a nitric oxide signal whose generation is itself partly androgen-dependent. A man with untreated hypogonadism from any cause may respond poorly to a PDE5 inhibitor that would otherwise be effective.
What the Epidemiology Shows
The most frequently cited epidemiological evidence is a population-based case-control study published in The Journal of Sexual Medicine, which examined the association between varicocele, varicocelectomy, and erectile dysfunction in a large administrative dataset. The authors noted at the outset that while the fertility literature on varicocele treatment is extensive, evidence on erectile dysfunction was comparatively sparse; their analysis found a significant association between varicocele and erectile dysfunction [3].
Population-based designs of this kind carry the usual limitations. They rely on diagnostic coding rather than direct examination, they cannot establish causal direction, and they are vulnerable to detection bias — men who present to a urologist for one genitourinary complaint are more likely to have a second one recorded. A man being worked up for varicocele is simply more likely to be asked about erectile function than a man who never attends a urology clinic.
What raises the finding above the level of a coding artefact is that it is mechanistically predicted. The hypothesis that varicocele lowers testosterone, and that lower testosterone impairs erectile function, was established independently of the epidemiology. The association is what that hypothesis predicts.
Evidence From Varicocelectomy
Intervention data are more informative than association data, and here the literature is directly relevant. A study in The Journal of Sexual Medicine assessed the impact of varicocelectomy on gonadal and erectile function in men with both hypogonadism and infertility, having noted that prior reports had linked varicocele in infertile men to Leydig cell dysfunction. The study examined serum total testosterone and erectile function together as outcomes following repair [4].
A review in the Asian Journal of Andrology addressed the clinical decision directly, framing hypogonadism and erectile dysfunction as an emerging indication for varicocele repair. Its practical guidance was conservative and worth repeating: men with hypogonadal symptoms should have at least two serum testosterone measurements before conclusions are drawn, and microsurgical varicocelectomy may be beneficial for men with clinically palpable varicoceles and documented hypogonadism [5].
Two qualifications matter. The benefit is reported for clinically palpable varicoceles, not for subclinical ones detected only on ultrasound — a distinction that is frequently lost in consumer health writing. And the men studied were selected for documented hypogonadism, so the results do not generalise to men with normal testosterone and an incidental varicocele. Clinical studies suggest benefit in a defined subgroup; some men experience improvement in erectile function after repair, and the evidence does not support presenting repair as an erectile dysfunction treatment in general.
Who Should Actually Be Evaluated
The practical synthesis is narrow but useful. A man with erectile dysfunction, low or borderline testosterone on repeated morning measurement, and a palpable varicocele on examination has a potentially correctable contributor that a prescription alone will not address. That combination warrants urological assessment rather than immediate escalation of pharmacological therapy.
Conversely, a man with erectile dysfunction and normal testosterone is unlikely to have a varicocele as the principal cause, even if one is present — varicoceles are common, and co-occurrence is not causation. The far more common drivers of erectile dysfunction in men over forty remain vascular and metabolic: endothelial dysfunction, hypertension, dyslipidaemia, insulin resistance, and smoking.
For most men, pharmacological therapy remains the appropriate first line and is well supported. A 2026 systematic review and network meta-analysis in The Journal of Sexual Medicine confirmed the consistent efficacy of on-demand PDE5 inhibitors over placebo across randomized double-blind trials, while emphasising that erectile dysfunction is a multifactorial condition with vascular, hormonal, neurological, and psychological contributors [6]. The word doing the work in that sentence is hormonal. Identifying which contributor dominates in an individual man is the point of a proper evaluation, and it is the reason a physician assessment should precede treatment rather than follow it.
Conclusion
The relationship between varicocele and erectile dysfunction is real, mechanistically coherent, and narrower than it first appears. It operates through Leydig cell dysfunction and reduced testosterone rather than through impaired penile perfusion, which means it matters most for the specific subgroup of men who have a palpable varicocele together with documented hypogonadism. For those men, repair addresses an upstream cause that medication alone leaves in place. For everyone else, a varicocele is more likely an incidental finding than an explanation — and the useful clinical question remains which mechanism is actually failing.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans starting with a free online assessment at questionnaire.getonyxmd.com. You can read more about the EPIQ CHEWS formulation or browse further clinical articles on the OnyxMD blog.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
- Barone B, Amicuzi U, Tammaro S, et al. Male infertility: a comprehensive review of urological causes and contemporary management. Journal of Clinical Medicine. 2026;15(1):397. doi:10.3390/jcm15010397
- Hayden RP, et al. Testosterone and varicocele. Urologic Clinics of North America. 2016;43(2):223-232. doi:10.1016/j.ucl.2016.01.009
- Keller JJ, Chen YK, Lin HC. Varicocele is associated with erectile dysfunction: a population-based case-control study. The Journal of Sexual Medicine. 2012;9(7):1745-1752. doi:10.1111/j.1743-6109.2012.02736.x
- Zohdy W, Ghazi S, Arafa M. Impact of varicocelectomy on gonadal and erectile functions in men with hypogonadism and infertility. The Journal of Sexual Medicine. 2011;8(3):885-893. doi:10.1111/j.1743-6109.2010.01974.x
- Dabaja AA, Goldstein M. When is a varicocele repair indicated: the dilemma of hypogonadism and erectile dysfunction? Asian Journal of Andrology. 2016;18(2):213-216. doi:10.4103/1008-682X.169560
- Salonia A, Bettocchi C, Burnett A, Corona G, Fode M, Hassan T, Minhas S, Mulhall JP, Sadeghi-Nejad H, Vignesh SO, Wang R, Jannini EA. A comparative evaluation of on-demand phosphodiesterase-5 inhibitor efficacy in erectile dysfunction treatment: a systematic review and network meta-analysis of double-blind, placebo-controlled, randomized trials. The Journal of Sexual Medicine. 2026;23(7):qdag176. doi:10.1093/jsxmed/qdag176
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.